Cross-Market Price Comparison
| Other Listed Market | Shanghai (SSE) — 药明康德 |
|---|---|
| Other Market Stock Code | 603259 |
| H-Share Offer Price | To be extracted |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | 無錫藥明康德新藥開發股份有限公司 - Ｈ股 |
|---|---|
| Stock Code | 02359 |
| Company Full Name | 無錫藥明康德新藥開發股份有限公司 - Ｈ股 |
| Industry | 醫療保健 |
| Principal Activities | 公司主要從事藥物研發平臺業務，包括發現、研發及生產小分子藥物、細胞療法及基因療法，以及提供醫療器械測試服務等。 |
| Listing Date | 2018-12-13 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市外高橋自貿區富特中路288號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.wuxiapptec.com.cn |
| Share Registrar | |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 68.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 792,036,800 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 68.0 |
|---|---|
| First Day Open | HK$ 67.0 |
| First Day Change | 88.09% |
| First Day Volume | 20214000.0 |
| First Day Turnover | 1355050000.0 |
Use of Proceeds
| Use of Proceeds | 1、約36.9%（即約2,798.0百萬港元）用于擴大全球所有業務單位的生產力及能力； 2、約26.5%（即約2,000.0百萬港元）用于收購CRO及CMO/CDMO公司； 3、約4.0%（即約300.0百萬港元）用于投資及培育健康業界有創新業務模式且有增長潛力的公司，以投資我們的生態體系； 4、約2.6%（即約200.0百萬港元）用于開發高端科技； 5、約19.9%（即約1,500百萬港元）用于償還最后可行日期的未償還選定銀行貸款； 6、約10.0%（即約755.3百萬港元）撥作營運資金及一般公司用途。 |
|---|
Underwriting Syndicate
Joint Sponsors (3)
摩根士丹利亚洲有限公司 CE AAD291
华泰金融控股（香港）有限公司 CE AOK809
高盛（亚洲）有限责任公司 CE ACC536
Overall Coordinators (5)
摩根士丹利亚洲有限公司 CE AAD291
华泰金融控股（香港）有限公司 CE AOK809
高盛（亚洲）有限责任公司 CE ACC536
UBS Securities Hong Kong Limited CE BIN466
招商证券（香港）有限公司 CE AAI650
Joint Bookrunners (8)
摩根士丹利亚洲有限公司 CE AAD291
华泰金融控股（香港）有限公司 CE AOK809
高盛（亚洲）有限责任公司 CE ACC536
UBS Securities Hong Kong Limited CE BIN466
招商证券（香港）有限公司 CE AAI650
华兴证券（香港）有限公司 CE AZX839
中银国际亚洲有限公司 CE AET863
中信里昂证券有限公司 CE AAB893
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Chairman | 李革 |
|---|---|
| Company Secretary | 韓敏;張月芬 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 李革及關連人士(25.03%);淡馬錫控股(私人)有限公司(5.38%) |
|---|
